Kalpit Patel
Stock Analyst at B. Riley Securities
(2.20)
# 1,507
Out of 4,413 analysts
33
Total ratings
38.71%
Success rate
-0.47%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PDSB PDS Biotechnology | Reiterates: Buy | $14 → $11 | $3.61 | +204.71% | 3 | Mar 28, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $29 → $25 | $13.81 | +81.03% | 2 | Mar 21, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $1.25 | $1.09 | +14.68% | 3 | Mar 6, 2024 | |
| XFOR X4 Pharmaceuticals | Downgrades: Neutral | $3 → $1 | $1.11 | -9.50% | 1 | Dec 12, 2023 | |
| VSTM Verastem | Reiterates: Buy | $21 | $9.98 | +110.42% | 2 | Sep 29, 2023 | |
| BCYC Bicycle Therapeutics | Upgrades: Buy | $33 | $24.20 | +36.36% | 4 | Sep 12, 2023 | |
| DERM Journey Medical | Reiterates: Buy | $6 | $3.51 | +70.94% | 4 | Sep 7, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $34 → $36 | $21.97 | +63.86% | 2 | Jul 25, 2023 | |
| LBPH Longboard Pharmaceuticals | Initiates: Buy | $13 | $21.96 | -40.80% | 1 | Apr 27, 2023 | |
| GERN Geron | Reiterates: Buy | $5 | $4.08 | +22.55% | 2 | Mar 20, 2023 | |
| INAB IN8bio | Downgrades: Neutral | $9 → $3 | $1.05 | +187.08% | 2 | Nov 11, 2022 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $21 → $18 | $2.92 | +516.44% | 1 | Sep 22, 2022 | |
| ENTX Entera Bio | Maintains: Buy | $6 → $5 | $2.00 | +150.00% | 1 | Jul 19, 2022 | |
| VINC Vincerx Pharma | Maintains: Buy | $12 → $6 | $0.89 | +574.76% | 2 | Jun 7, 2022 | |
| INKT MiNK Therapeutics | Maintains: Buy | $24 → $10 | $0.95 | +949.87% | 1 | Jan 24, 2022 | |
| KYMR Kymera Therapeutics | Initiates: Neutral | n/a | $36.24 | - | 1 | Sep 30, 2021 | |
| FBRX Forte Biosciences | Downgrades: Neutral | n/a | $0.67 | - | 1 | Sep 3, 2021 |
PDS Biotechnology
Mar 28, 2024
Reiterates: Buy
Price Target: $14 → $11
Current: $3.61
Upside: +204.71%
Viridian Therapeutics
Mar 21, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $13.81
Upside: +81.03%
Rigel Pharmaceuticals
Mar 6, 2024
Maintains: Neutral
Price Target: $1.25
Current: $1.09
Upside: +14.68%
X4 Pharmaceuticals
Dec 12, 2023
Downgrades: Neutral
Price Target: $3 → $1
Current: $1.11
Upside: -9.50%
Verastem
Sep 29, 2023
Reiterates: Buy
Price Target: $21
Current: $9.98
Upside: +110.42%
Bicycle Therapeutics
Sep 12, 2023
Upgrades: Buy
Price Target: $33
Current: $24.20
Upside: +36.36%
Journey Medical
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $3.51
Upside: +70.94%
Syndax Pharmaceuticals
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $21.97
Upside: +63.86%
Longboard Pharmaceuticals
Apr 27, 2023
Initiates: Buy
Price Target: $13
Current: $21.96
Upside: -40.80%
Geron
Mar 20, 2023
Reiterates: Buy
Price Target: $5
Current: $4.08
Upside: +22.55%
IN8bio
Nov 11, 2022
Downgrades: Neutral
Price Target: $9 → $3
Current: $1.05
Upside: +187.08%
Allogene Therapeutics
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $2.92
Upside: +516.44%
Entera Bio
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $2.00
Upside: +150.00%
Vincerx Pharma
Jun 7, 2022
Maintains: Buy
Price Target: $12 → $6
Current: $0.89
Upside: +574.76%
MiNK Therapeutics
Jan 24, 2022
Maintains: Buy
Price Target: $24 → $10
Current: $0.95
Upside: +949.87%
Kymera Therapeutics
Sep 30, 2021
Initiates: Neutral
Price Target: n/a
Current: $36.24
Upside: -
Forte Biosciences
Sep 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.67
Upside: -